Presence of human papillomaviruses and p16 expression in hypopharyngeal cancer.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 23737140.
- Also identified by DOI 10.1002/hed.23394.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with hypopharyngeal cancer have a 5-year survival of only 15% to 30%. Human papillomavirus (HPV) is a risk factor and a favorable prognostic factor for oropharyngeal carcinoma and p16 has been suggested as a surrogate marker for HPV-induced cancer. However, few studies have been performed on HPV and p16 in hypopharyngeal cancer. One hundred nine pretreatment hypopharyngeal cancer biopsies were analyzed for presence of HPV and p16 overexpression, and the results were correlated to patient survival. Of 109 tumors, 7 were HPV-positive (4 HPV16) and 18 overexpressed p16. There was some correlation between survival and HPV status, but not with regard to p16 expression. Notably, all patients with HPV16-positive tumors, also overexpressing p16, lived tumor free for more than 3 years. Our results indicate that HPV-induced hypopharyngeal cancer is rare and that p16 is not a suitable biomarker for presence of HPV in this tumor type.
Medical subject headings
- Biomarkers, Tumor
- Cyclin-Dependent Kinase Inhibitor p16
- Gene Expression Regulation, Neoplastic
- Human papillomavirus 16
- Hypopharyngeal Neoplasms